Platelet Response to Clopidogrel Is Attenuated in Diabetic Patients Undergoing Coronary Stent Implantation

Open Access
Publisher Website
Google Scholar
Abstract
Type 2 diabetic and nondiabetic patients treated by coronary stenting for symptomatic CAD were consecutively enrolled in this study. The protocol was approved by the local ethics committee, and signed informed consent was obtained from all patients. Patients with known platelet function disorders, thrombocytopenia (5 cells/mm3), or any contraindications against clopidogrel were excluded. A loading dose of 600 mg clopidogrel was given to all patients before PCI, followed by 75 mg every day. All patients received a daily dose of 100 mg aspirin before PCI. A standard dose of heparin was given to all patients immediately before PCI unless there were no contraindications. Type 2 diabetes was defined according to the recommendations of the American Diabetes Association (13).